186 related articles for article (PubMed ID: 20656030)
1. Inverse association between CSF Aβ 42 levels and years of education in mild form of Alzheimer's disease: the cognitive reserve theory.
Dumurgier J; Paquet C; Benisty S; Kiffel C; Lidy C; Mouton-Liger F; Chabriat H; Laplanche JL; Hugon J
Neurobiol Dis; 2010 Nov; 40(2):456-9. PubMed ID: 20656030
[TBL] [Abstract][Full Text] [Related]
2. Assessment of cerebrospinal fluid (CSF) beta-amyloid (1-42), phosphorylated tau (ptau-181) and total Tau protein in patients with Alzheimer's disease (AD) and other dementia at Siriraj Hospital, Thailand.
Thaweepoksomboon J; Senanarong V; Poungvarin N; Chakorn T; Siwasariyanon N; Washirutmangkur L; Udompunthuruk S
J Med Assoc Thai; 2011 Feb; 94 Suppl 1():S77-83. PubMed ID: 21721431
[TBL] [Abstract][Full Text] [Related]
3. Cystatin C levels are positively correlated with both Abeta42 and tau levels in cerebrospinal fluid in persons with Alzheimer's disease, mild cognitive impairment, and healthy controls.
Sundelöf J; Sundström J; Hansson O; Eriksdotter-Jönhagen M; Giedraitis V; Larsson A; Degerman-Gunnarsson M; Ingelsson M; Minthon L; Blennow K; Kilander L; Basun H; Lannfelt L
J Alzheimers Dis; 2010; 21(2):471-8. PubMed ID: 20555147
[TBL] [Abstract][Full Text] [Related]
4. CSF biomarkers in relationship to cognitive profiles in Alzheimer disease.
van der Vlies AE; Verwey NA; Bouwman FH; Blankenstein MA; Klein M; Scheltens P; van der Flier WM
Neurology; 2009 Mar; 72(12):1056-61. PubMed ID: 19307538
[TBL] [Abstract][Full Text] [Related]
5. CSF Aβ₁₋₄₂ levels and glucose metabolism in Alzheimer's disease.
Dumurgier J; Paquet C; Peoc'h K; Lapalus P; Mouton-Liger F; Benisty S; Chasseigneaux S; Chabriat H; Hugon J
J Alzheimers Dis; 2011; 27(4):845-51. PubMed ID: 21897007
[TBL] [Abstract][Full Text] [Related]
6. Association between cerebrospinal fluid tau and brain atrophy is not related to clinical severity in the Alzheimer's disease continuum.
Solé-Padullés C; Lladó A; Bartrés-Faz D; Fortea J; Sánchez-Valle R; Bosch B; Antonell A; Molinuevo JL; Rami L
Psychiatry Res; 2011 Jun; 192(3):140-6. PubMed ID: 21546220
[TBL] [Abstract][Full Text] [Related]
7. Value of CSF beta-amyloid1-42 and tau as predictors of Alzheimer's disease in patients with mild cognitive impairment.
Hampel H; Teipel SJ; Fuchsberger T; Andreasen N; Wiltfang J; Otto M; Shen Y; Dodel R; Du Y; Farlow M; Möller HJ; Blennow K; Buerger K
Mol Psychiatry; 2004 Jul; 9(7):705-10. PubMed ID: 14699432
[TBL] [Abstract][Full Text] [Related]
8. Could clinical profile influence CSF biomarkers in early-onset Alzheimer disease?
Koric L; Felician O; Guedj E; Hubert AM; Mancini J; Boucraut J; Ceccaldi M
Alzheimer Dis Assoc Disord; 2010; 24(3):278-83. PubMed ID: 20473135
[TBL] [Abstract][Full Text] [Related]
9. CSF biomarkers predict rate of cognitive decline in Alzheimer disease.
Kester MI; van der Vlies AE; Blankenstein MA; Pijnenburg YA; van Elk EJ; Scheltens P; van der Flier WM
Neurology; 2009 Oct; 73(17):1353-8. PubMed ID: 19858456
[TBL] [Abstract][Full Text] [Related]
10. Tau-proteins as gender-specific state markers in amnestic mild cognitive impairment.
Riepe MW; Karl J; Tumani H; von Arnim CA
Dement Geriatr Cogn Disord; 2010; 30(2):93-100. PubMed ID: 20720423
[TBL] [Abstract][Full Text] [Related]
11. Cerebrospinal fluid amyloid beta(1-42) levels in the mild cognitive impairment stage of Alzheimer's disease.
Maruyama M; Arai H; Sugita M; Tanji H; Higuchi M; Okamura N; Matsui T; Higuchi S; Matsushita S; Yoshida H; Sasaki H
Exp Neurol; 2001 Dec; 172(2):433-6. PubMed ID: 11716567
[TBL] [Abstract][Full Text] [Related]
12. Correlation between cognitive impairment and CSF biomarkers in amnesic MCI, non-amnesic MCI, and Alzheimer's disease.
Haldenwanger A; Eling P; Kastrup A; Hildebrandt H
J Alzheimers Dis; 2010; 22(3):971-80. PubMed ID: 20858947
[TBL] [Abstract][Full Text] [Related]
13. Cerebrospinal fluid biomarkers and memory present distinct associations along the continuum from healthy subjects to AD patients.
Rami L; Fortea J; Bosch B; Solé-Padullés C; Lladó A; Iranzo A; Sánchez-Valle R; Molinuevo JL
J Alzheimers Dis; 2011; 23(2):319-26. PubMed ID: 21098971
[TBL] [Abstract][Full Text] [Related]
14. BACE1 activity in cerebrospinal fluid and its relation to markers of AD pathology.
Mulder SD; van der Flier WM; Verheijen JH; Mulder C; Scheltens P; Blankenstein MA; Hack CE; Veerhuis R
J Alzheimers Dis; 2010; 20(1):253-60. PubMed ID: 20164582
[TBL] [Abstract][Full Text] [Related]
15. Cerebrospinal fluid {beta}-amyloid 42 and tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain.
Tapiola T; Alafuzoff I; Herukka SK; Parkkinen L; Hartikainen P; Soininen H; Pirttilä T
Arch Neurol; 2009 Mar; 66(3):382-9. PubMed ID: 19273758
[TBL] [Abstract][Full Text] [Related]
16. Cerebrospinal fluid markers for Alzheimer's disease over the lifespan: effects of age and the APOEε4 genotype.
Popp J; Lewczuk P; Frommann I; Kölsch H; Kornhuber J; Maier W; Jessen F
J Alzheimers Dis; 2010; 22(2):459-68. PubMed ID: 21084733
[TBL] [Abstract][Full Text] [Related]
17. [The role of CSF markers in the early diagnosis of Alzheimer's disease].
Vos SJ; Visser PJ; Verhey FR
Tijdschr Psychiatr; 2011; 53(9):647-53. PubMed ID: 21898322
[TBL] [Abstract][Full Text] [Related]
18. No association of CSF biomarkers with APOEepsilon4, plaque and tangle burden in definite Alzheimer's disease.
Engelborghs S; Sleegers K; Cras P; Brouwers N; Serneels S; De Leenheir E; Martin JJ; Vanmechelen E; Van Broeckhoven C; De Deyn PP
Brain; 2007 Sep; 130(Pt 9):2320-6. PubMed ID: 17586559
[TBL] [Abstract][Full Text] [Related]
19. PSEN1 mutation carriers present lower cerebrospinal fluid amyoid-β42 levels than sporadic early-onset Alzheimer's disease patients but no differences in neuronal injury biomarkers.
Balasa M; Vidal-Piñeiro D; Lladó A; Antonell A; Bosch B; Castellanos F; Bargalló N; Bartres-Faz D; Molinuevo JL; Sánchez-Valle R
J Alzheimers Dis; 2012; 30(3):605-16. PubMed ID: 22426017
[TBL] [Abstract][Full Text] [Related]
20. Cerebrospinal fluid beta-amyloid1-42 and tau in control subjects at risk for Alzheimer's disease: the effect of APOE epsilon4 allele.
Sunderland T; Mirza N; Putnam KT; Linker G; Bhupali D; Durham R; Soares H; Kimmel L; Friedman D; Bergeson J; Csako G; Levy JA; Bartko JJ; Cohen RM
Biol Psychiatry; 2004 Nov; 56(9):670-6. PubMed ID: 15522251
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
